By this point Yen Choo who's half Chinese and half Greek, his name is actually Evgenios, the Greek, but he can't bear to be called Evgenios, his mother's Greek and as you know... he has an entrepreneurial side... he decided he's going to leave the lab, he could have stayed on, and set up a company to compete with Sangamo because Sangamo had done that. So he did succeed in raising finance and he recruited Michael Moore and... Mark Isalan students, one was a post doc other was a student in the lab and he did, he set up a company at the MRC technology incubator in Mill Hill and he built quite a good... he built a research establishment, it was difficult to raise finance, in the meantime, Sangamo went from strength to strength and they floated, at the peak of the high tech of the dotcom boom, so he floated the company, went public and raised $150 million which would keep the company going for many years. And by this time, he was attracting good people, he'd attracted Carl Pabo to come and work for him. Carl Pabo the crystallographer to become a CEO. I'm not that that was a good choice, he's no longer the CEO because although he's an absolutely marvellous crystallographer, I'm not sure how strong his biological instincts are, but he's very, very efficient and he read books on managerial, managing and all that, rather a bad sign. So what happened is that, to make a short story of it, Sangamo acquired... they bought out the investors in the MRC company which was called Gendaq, 'gen' for gene and 'daq' for Greek 'dactile finger'. It was Gendaq and with them they bought all the MRC patents, the MRC patents were devolved on Sangamo. I'll be talking about transcript technology later on. But this was one of the things where I saw to it that we always patented everything we could. And the MRC held the patents, so the... so what happened was that the... so the libraries we built up of the two times three fingers and three times two fingers were all passed onto Sangamo and the work I'm going to describe. I don't know when I'm going to do this, perhaps after lunch, used our libraries. Originally our Cambridge libraries which went to Gendaq to improve in Gendaq. So I just tell you this episode, why this is important because the work that is now being done in therapeutic applications is being done by this company called Sangamo, but using our know-how and I'm on the scientific advisory board of Sangamo, as was Yen Choo but then he decided to leave and he's now set up yet another company. So those are the connections, but they are part of the story.
